Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Giladi

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Heart Rhythm|March 7, 2026
Risk Stratification in the Short-QT Syndrome: Findings From a Pooled AnalysisMoshe Giladi, Aviv Solomon, Dana Viskin, et al.
The British Journal of Dermatology|May 13, 2025
Loss-of-function variants in DUSP1 encoding dual specificity phosphatase 1 cause palmoplantar keratodermaKiril Malovitski, Yarden Feller, Moshe Giladi, et al.
Scientific Reports|December 15, 2015
Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer CellsMoshe Giladi, Rosa S Schneiderman, Tali Voloshin, et al.
Biomolecules|October 27, 2022
Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In VivoEllaine Salvador, Almuth F Kessler, Dominik Domröse, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2020
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyTali Voloshin, Noa Kaynan, Shiri Davidi, et al.
STAR Protocols|January 10, 2025
Protocol for applying Tumor Treating Fields in mouse models of cancer using the inovivo systemTravis J Gates, Sewar Zbidat, Karina Deniz, et al.
International Journal of Cancer|August 26, 2016
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoTali Voloshin, Mijal Munster, Roni Blatt, et al.
Cancers|June 24, 2022
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
Cancers|February 25, 2023
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>. <i>Cancers</i> 2022, <i>14</i>, 2959Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
Frontiers in Oncology|July 12, 2024
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistanceYani Berckmans, Hila M Ene, Kerem Ben-Meir, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Heart Rhythm|March 7, 2026
Risk Stratification in the Short-QT Syndrome: Findings From a Pooled AnalysisMoshe Giladi, Aviv Solomon, Dana Viskin, et al.
The British Journal of Dermatology|May 13, 2025
Loss-of-function variants in DUSP1 encoding dual specificity phosphatase 1 cause palmoplantar keratodermaKiril Malovitski, Yarden Feller, Moshe Giladi, et al.
Scientific Reports|December 15, 2015
Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer CellsMoshe Giladi, Rosa S Schneiderman, Tali Voloshin, et al.
Biomolecules|October 27, 2022
Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In VivoEllaine Salvador, Almuth F Kessler, Dominik Domröse, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2020
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyTali Voloshin, Noa Kaynan, Shiri Davidi, et al.
STAR Protocols|January 10, 2025
Protocol for applying Tumor Treating Fields in mouse models of cancer using the inovivo systemTravis J Gates, Sewar Zbidat, Karina Deniz, et al.
International Journal of Cancer|August 26, 2016
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoTali Voloshin, Mijal Munster, Roni Blatt, et al.
Cancers|June 24, 2022
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
Cancers|February 25, 2023
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>. <i>Cancers</i> 2022, <i>14</i>, 2959Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
Frontiers in Oncology|July 12, 2024
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistanceYani Berckmans, Hila M Ene, Kerem Ben-Meir, et al.
Pageof 10